A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation

NCT05090371 · clinicaltrials.gov ↗

PHASE4

Phase

ACTIVE_NOT_RECRUITING

Status

136

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsing-Remitting Multiple Sclerosis

Interventions

DRUG: Ofatumumab
DRUG: Disease modifying treatment (DMT)

Sponsor

Novartis Pharmaceuticals